Nice says Bayer’s Eylea not recommended as first-line treatment in draft recommendation
June 10, 2016Medical Communications, Research and Development Bayer, Eylea, NICE, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) in a provisional guidance said Bayer’s (ETR: BAYN) Eylea (aflibercept) is …
FDA targets online illegal prescription drugs sellers
June 10, 2016Medical Communications, Sales and Marketing FDA, Ireland, illegal drug sales
The US Food and Drug Administration (FDA), in partnership with an INTERPOL-led global collaborative effort, has announced that it has …
Amgen, Novartis migraine drug meets primary endpoint in Phase II study
June 9, 2016Research and Development AMG 334, Amgen, Novartis, Phase II, chronic, erenumab, migraine
A new treatment for chronic migraine prevention, co-developed by Novartis (NYSE: NVS) and Amgen (NASDAQ: AMGN), showed a statistically significant …
GSK, Janssen RA treatment meets co-primary endpoints in Phase III trial
June 9, 2016Research and Development GSK, Janssen, eular 2016, rheumatoid arthritis, sirukumab
GSK (LSE: GSK) and Janssen, a division of Johnson and Johnson, have announced data from a pivotal Phase III study …
Sandoz biosimilars as safe and efficacious as originators, says early trials data
June 9, 2016Research and Development Enbrel, MabThera, Novartis, Sandoz, biosimilars, etanercept, rituximab
Sandoz, a division of Novartis, has presented data at the Annual European Congress of Rheumatology (EULAR 2016) demonstrating the safety …
AstraZeneca sells rights to anaesthetics products to Aspen for $520 million upfront
June 9, 2016Research and Development, Sales and Marketing AstraZeneca, Licencing, anaesthetics, aspen, marketing agreement
UK drug firm AstraZeneca (LSE: AZN) on Thursday said it has agreed to sell rights for its anaesthetics portfolio to Aspen …
Clarissa Lewis joins the Clinical Trials Team at Woodley Equipment Company
June 8, 2016Medical Equipment Supplier, medical equip rental, woodley equipment
We are pleased to welcome Clarissa Lewis to Woodley Equipment Company Clinical Trials Division as Accounts Supervisor based at our …
New data on biosimilars of the big three anti-TNF drugs presented at EULAR 2016
June 8, 2016Research and Development, Sales and Marketing Benepali, Biogen, Enbrel, Flixabi, Humira, Remicade, Samsung Bioepis, biosimilars, eular 2016, sb5
Samsung Bioepis has presented data at EULAR 2016 on three biosimilars of the highly selling anti-TNF drugs Remicade (infliximab), Enbrel …
India-based Cipla gets new chief financial officer
June 8, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cipla, Dr Reddy's, cfo, dr reddys
Cipla (NSE: CIPLA) has poached a top executive from Dr. Reddy’s by naming Kedar Upadhye as its new global chief …
Novartis to compare Cosentyx with Humira in new clinical trials
June 8, 2016Research and Development Cosentyx, Humira, Novartis, comparison, eular 2016
Novartis has announced that it plans to directly compare Cosentyx (secukinumab) versus Humira (adalimumab) in patients with ankylosing spondylitis and …
Biogen MS drug misses primary endpoint in Phase II trial
June 8, 2016Research and Development Biogen, MS, multiple sclerosis, opicinumab
Biogen has reported top-line results in the Phase II trial evaluating opicinumab (anti-Lingo-1) in relapsing forms of multiple sclerosis, with …
Losses and profit forecast cuts send shares tumbling again at Valeant
June 8, 2016Research and Development, Sales and Marketing Shares, Valeant, cut, forecast, tumbling
Valeant Pharmaceuticals has published its results for the first quarter, which has seen the firm post a net loss of …
Roche says combination therapy with its Avastin and Tarceva gets European backing for lung cancer treatment
June 8, 2016Research and Development, Sales and Marketing European Commission, NSCL, RegulationC, Roche, Tarceva, avastin, drug trial, lung cancer
Cancer drugmaker Roche (SIX: ROG) on Wednesday said the European Commission has approved its Avastin (bevacizumab) in combination with Tarceva …
MSD says Phase III trials for Keytruda to treat advanced melanoma shows better survival
June 8, 2016Research and Development ASCO, MSD, Merck & Co, PD-L1, advanced melanoma, drug trial, immuno-oncology, keytruda
Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced melanoma showed over half …
MSD to collaborate with Fujifilm Diosynth on new microbial biologics facility
June 7, 2016Manufacturing and Production, Research and Development MSD, Merck, fujifilm diosynth
MSD, known as Merck in the US and Canada, has entered into a collaboration with Fujifilm Diosynth Biotechnologies to invest …
Drug Pricing: Cancer drugs cost the most in US, but most unaffordable in India, China – Study
June 7, 2016Medical Communications, Research and Development, Sales and Marketing ASCO, Drug pricing, oncology, social
Cancer drugs are less affordable in low-income countries, despite the lower retail prices, according to a study released at the …
The Pharmafocus ASCO round-up
June 7, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, Pharmafocus
As the curtain falls on another annual ASCO (American Society of Clinical Oncology) congress, catch up on all the biggest …
AstraZeneca says latest study data for Lynparza suggest improvement in overall survival in ovarian cancer
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AstraZeneca, NHS, lynparza, ovarian cancer, regulation
UK drugmaker AstraZeneca (LSE: AZN) said mid-stage trials for Lynparza (olaparib) maintenance therapy suggest an improvement in overall survival (OS) …
Judge reverses verdict in MSD/Gilead hepatitis C dispute
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Gilead, MSD, Merck, dispute, patent, reversal, sovaldi
A US district judge has reversed a previous court decision which favoured MSD, called Merck in the US, over Gilead …
FDA approves Allergan hypertension fixed-dose combo, Byvalson
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, FDA, US, angiotensin ii, approval, beta blocker, byvalson, hypertension, nebivolol, valsartan
Allergan has announced that the US Food and Drug Administration (FDA) has approved its fixed-dose combination, Byvalson (nebivolol and valsartan), …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
